BeiGene
.png){kind=logo}
Chinese biotechnology company
BeiGene, Ltd.
| Type | Public |
|---|---|
| Traded as | NASDAQ: BGNE , SEHK: Script error: No such module "Leading zeros".&sc_lang=en Script error: No such module "Leading zeros". |
| Key people | John V. Oyler (CEO) |
| Industry | Biotechnology |
| Products | Cancer treatments |
BeiGene, Ltd. is a global, commercial-stage biotechnology company focused on developing and commercializing innovative molecularly targeted and immuno-oncology drug candidates for the treatment of cancer. The company was founded in 2010 by John V. Oyler and Xiaodong Wang and is headquartered in Beijing, China.
History[edit | edit source]
BeiGene was established in 2010 with the aim of creating a world-class biotechnology company in China. The company has since expanded its operations globally, with offices and facilities in the United States, Australia, and various other countries.
Research and Development[edit | edit source]
BeiGene's research and development efforts are primarily focused on oncology. The company has a broad pipeline of drug candidates, including both small molecules and biologics. Key areas of research include immuno-oncology, molecularly targeted therapy, and combination therapy.
Products[edit | edit source]
BeiGene has developed several drug candidates that are in various stages of clinical development. Some of the notable products include:
- Brukinsa (zanubrutinib): A Bruton's tyrosine kinase (BTK) inhibitor for the treatment of mantle cell lymphoma and other B-cell malignancies.
- Tislelizumab: An anti-PD-1 antibody for the treatment of various types of cancer.
Collaborations and Partnerships[edit | edit source]
BeiGene has entered into several strategic collaborations and partnerships with leading pharmaceutical companies to advance its drug development programs. These partnerships include collaborations with companies such as Celgene, Amgen, and Novartis.
Stock Market[edit | edit source]
BeiGene is publicly traded on the NASDAQ under the ticker symbol BGNE and on the Hong Kong Stock Exchange under the ticker symbol 6160.
See also[edit | edit source]
Related pages[edit | edit source]
 | This biotechnology article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
